The critical role of PPARγ in human malignant melanoma

PPAR Research

Volumn , Issue , 2008, Pages

  Freudlsperger, Christian ^a   Schumacher, Udo ^b   Reinert, Siegmar ^a   Hoffmann, Jürgen ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2 CHLORO 5 NITROBENZANILIDE; BEZAFIBRATE; BORTEZOMIB; CIGLITAZONE; GLITAZONE DERIVATIVE; PEROXISOME PROLIFERATOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PIRINIXIC ACID; ROSIGLITAZONE; SORAFENIB; TROGLITAZONE;

CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSCRIPTION; GROWTH INHIBITION; HUMAN; KERATINOCYTE; MELANOCYTE; MELANOMA; MELANOMA CELL; NICK END LABELING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 44049098914     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2008/503797     Document Type: Review

References (39)

1. Wolchok J. D., Livingston P. O., Vaccines for melanoma: translating basic immunology into new therapies Lancet Oncology 2001 2 4 205 211
2. Serrone L., Zeuli M., Sega F. M., Cognetti F., Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview Journal of Experimental and Clinical Cancer Research 2000 19 1 21 34
3. Davies H., Bignell G. R., Cox C., Mutations of the BRAF gene in human cancer Nature 2002 417 6892 949 954
4. Garnett M. J., Marais R.
5. Luo J., Manning B. D., Cantley L. C.
6. Simpson L., Parsons R., PTEN: life as a tumor suppressor Experimental Cell Research 2001 264 1 29 41
7. Tsao H., Zhang X., Fowlkes K., Haluska F. G.
8. Huang S., DeGuzman A., Bucana C. D., Fidler I. J.
9. Amiri K. I., Horton L. W., LaFleur B. J., Sosman J. A., Richmond A.
10. Issemann I., Green S., Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators Nature 1990 347 6294 645 650
11. Mukherjee R., Jow L., Noonan D., McDonnell D. P., Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators Journal of Steroid Biochemistry and Molecular Biology 1994 51 3-4 157 166
12. Braissant O., Foufelle F., Scotto C., Dauca M., Wahli W., Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR- α,-β, and-γ in the adult rat Endocrinology 1996 137 1 354 366
13. Lemberger T., Desvergne B., Wahli W., Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology Annual Review of Cell and Developmental Biology 1996 12 335 363
14. Lehmann J. M., Moore L. B., Smith-Oliver T. A., Wilkison W. O., Willson T. M., Kliewer S. A., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ) Journal of Biological Chemistry 1995 270 22 12953 12956
15. Kubota T., Koshizuka K., Williamson E. A., Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo Cancer Research 1998 58 15 3344 3352
16. Elstner E.
17. Sarraf P., Mueller E., Jones D., Differentiation and reversal of malignant changes in colon cancer through PPAR γ Nature Medicine 1998 4 9 1046 1052
18. Tsubouchi Y., Sano H.
19. Sato H., Ishihara S., Kawashima K., Expression of peroxisome proliferator-activated receptor (PPAR) γ in gastric cancer and inhibitory effects of PPAR γ agonists British Journal of Cancer 2000 83 10 1394 1400
20. Motomura W., Okumura T., Takahashi N., Obara T., Kohgo Y., Activation of peroxisome proliferator-activated receptor γ by troglitazone inhibits cell growth through the increase of p 27 Kip 1 in human pancreatic carcinoma cells Cancer Research 2000 60 19 5558 5564
21. Guan Y.-F., Zhang Y.-H., Breyer R. M., Davis L., Breyer M. D.
22. Rivier M., Safonova I., Lebrun P., Griffiths C. E. M., Ailhaud G., Michel S., Differential expression of peroxisome proliferator-activated receptor subtypes during the differentiation of human keratinocytes Journal of Investigative Dermatology 1998 111 6 1116 1121
23. Westergaard M., Henningsen J., Svendsen M. L., Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid Journal of Investigative Dermatology 2001 116 5 702 712
24. Kang H. Y.
25. Kang H. Y.
26. Lee J. S., Choi Y. M., Kang H. Y.
27. Eastham L. L., Mills C. N., Niles R. M.
28. Freudlsperger C.
29. Mössner R., Schulz U., Krüger U., Agonists of peroxisome proliferator-activated receptor γ inhibit cell growth in malignant melanoma Journal of Investigative Dermatology 2002 119 3 576 582
30. Placha W.
31. Núñez N. P., Liu H., Meadows G. G.
32. Okano H., Shiraki K.
33. Straus D. S., Pascual G., Li M., 15-deoxy- Δ 12, 14 -prostaglandin J 2 inhibits multiple steps in the NF- κ B signaling pathway Proceedings of the National Academy of Sciences of the United States of America 2000 97 9 4844 4849
34. Freudlsperger C.
35. Han S.
36. Atallah E., Flaherty L.
37. Seimandi M., Lemaire G., Pillon A., Differential responses of PPAR α, PPAR δ, and PPAR γ reporter cell lines to selective PPAR synthetic ligands Analytical Biochemistry 2005 344 1 8 15
38. Clay C. E., Namen A. M., Atsumi G.-I., Magnitude of peroxisome proliferator-activated receptor- γ activation is associated with important and seemingly opposite biological responses in breast cancer cells Journal of Investigative Medicine 2001 49 5 413 420
39. Lucarelli E.